MX2014007735A - Antibiotic formulations. - Google Patents

Antibiotic formulations.

Info

Publication number
MX2014007735A
MX2014007735A MX2014007735A MX2014007735A MX2014007735A MX 2014007735 A MX2014007735 A MX 2014007735A MX 2014007735 A MX2014007735 A MX 2014007735A MX 2014007735 A MX2014007735 A MX 2014007735A MX 2014007735 A MX2014007735 A MX 2014007735A
Authority
MX
Mexico
Prior art keywords
antibiotic formulations
suspension formulation
antibiotic
formulations
administration
Prior art date
Application number
MX2014007735A
Other languages
Spanish (es)
Inventor
Karthigeyan Nanjan
Fadil Al Alawi
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014007735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of MX2014007735A publication Critical patent/MX2014007735A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068—Rumen, e.g. rumen bolus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A suspension formulation for administration to an animal, the suspension formulation including: at least one cephalosporin antibiotic or a pharmaceutically similar salt thereof; an oil; and a glycerol acetate solvent.
MX2014007735A 2011-12-23 2012-12-21 Antibiotic formulations. MX2014007735A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23
PCT/NZ2012/000245 WO2013095166A1 (en) 2011-12-23 2012-12-21 Antibiotic formulations

Publications (1)

Publication Number Publication Date
MX2014007735A true MX2014007735A (en) 2014-08-01

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007735A MX2014007735A (en) 2011-12-23 2012-12-21 Antibiotic formulations.

Country Status (15)

Country Link
KR (1) KR20140102319A (en)
CN (1) CN104080456A (en)
AU (1) AU2012359296B2 (en)
BR (1) BR112014014786A2 (en)
CL (1) CL2014001602A1 (en)
CO (1) CO7101241A2 (en)
CR (1) CR20140355A (en)
DO (1) DOP2014000146A (en)
IL (1) IL233299A0 (en)
MX (1) MX2014007735A (en)
MY (1) MY167596A (en)
NI (1) NI201400064A (en)
PE (1) PE20142373A1 (en)
PH (1) PH12014501384A1 (en)
WO (1) WO2013095166A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102113822B1 (en) 2012-07-17 2020-05-22 바이엘 뉴질랜드 리미티드 Injectable antibiotic formulations and their methods of use
US9452155B2 (en) 2012-07-17 2016-09-27 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
CA3132159C (en) 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR20040015622A (en) * 2002-08-13 2004-02-19 대한뉴팜(주) Injectable Composition Comprising Ceftiofur Sodium as Active Ingredient
CN1517090A (en) * 2003-01-20 2004-08-04 王玉万 Animal use suspensoid injection or emulsion containing antibacterial medicine
WO2009032843A2 (en) * 2007-09-06 2009-03-12 Auspex Pharmaceuticals, Inc. Deuterated ethambutols and their use
CN101401787B (en) * 2008-11-19 2011-05-18 肖希龙 Ceftiofur long-acting injection and preparation method thereof
CN101953889B (en) * 2010-09-07 2013-04-10 西北农林科技大学 Compound ceftiofur suspension emulsion injection and preparation method thereof

Also Published As

Publication number Publication date
PE20142373A1 (en) 2015-02-11
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22
IL233299A0 (en) 2014-08-31
CR20140355A (en) 2014-10-29
AU2012359296B2 (en) 2014-12-11
BR112014014786A2 (en) 2017-06-13
CN104080456A (en) 2014-10-01
CL2014001602A1 (en) 2014-10-24
DOP2014000146A (en) 2014-07-31
CO7101241A2 (en) 2014-10-31
NI201400064A (en) 2014-11-28
MY167596A (en) 2018-09-20
KR20140102319A (en) 2014-08-21
AU2012359296A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
MY174813A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
EP3082817A4 (en) Compositions for drug administration
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
MX2015012743A (en) Pyrazole-amide compound and medicinal uses therefor.
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
EP3030257A4 (en) Digestive enzyme composition suitable for enteral administration
EP3024475B8 (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
MX363530B (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR CORRESPONDING PHARMACEUTICALLY ACCEPTABLE SALT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE COMPONENT
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
PH12014501384A1 (en) Antibiotic formulations
HK1212978A1 (en) Novel derivatives of sinapinic acid
BR112014022687A2 (en) USE OF AN EFFECTIVE AMOUNT OF R-P88 OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, OR AN ESTER OF THE SAME OR A PHARMACEUTICALLY ACCEPTABLE SALT OF AN ESTER OF THE SAME, PHARMACEUTICAL COMPOSITION, R-P88 OR A PHARMACEUTICALLY ACCEPTABLE SALT, OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME OR A PHARMACEUTICALLY ACCEPTABLE SALT OF AN ESTER OF THE SAME
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2013095319A3 (en) Formulations of flurbiprofen and diacerein
MX2016005539A (en) Pharmaceutical compositions comprising antibacterial agents.
MX2016000775A (en) Pharmaceutical preparation comprising aminopyrazole derivative.
UY34839A (en) ANTIBIOTIC FORMULATIONS